

AMENDMENTS

In the claims

Please cancel claim 66 without prejudice or disclaimer.

Please amend claims 20, 26, 31-32, 35 and 39 as follows:

20. (Thrice amended) A polypeptide having immunological activity of anti-idiotype antibody 11D10, wherein the polypeptide comprises an immunoglobulin variable region containing three light chain complementarity determining regions (CDRs) of antibody 11D10, or an immunoglobulin variable region containing three heavy chain CDRs of antibody 11D10, wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC NO. HB 12020 or progeny thereof, and wherein the heavy chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC NO. HB 12020 or progeny thereof, and wherein the immunological activity of the polypeptide is an ability to stimulate a specific immune response against human milk fat globule (HMFG).

26. (Twice Amended) The polypeptide of claim 20, wherein the polypeptide contains a sequence of at least 2 contiguous amino acids which are identical in forward or reverse orientation to 2 contiguous amino acids of a tandem repeat sequence in human mucin from human milk fat globule, wherein said tandem repeat sequence is contained in SEQ ID NO:33.

31. (Twice amended) The fusion polypeptide of claim 27, which comprises three CDRs from the light chain variable region of 11D10 and three CDRs from the heavy chain variable region of 11D10.

F3
32. (Twice amended) The fusion polypeptide of claim 31, wherein the three CDRs from the light chain variable region of 11D10 and the three CDRs from the heavy chain variable region of 11D10 are linked by a linker polypeptide of about 5 to 20 amino acids.

F4
35. (Twice Amended) A humanized antibody comprising three CDRs from the light chain variable region of 11D10, three CDRs from the heavy chain variable region of 11D10, and a constant region that is a human sequence, wherein the humanized antibody is able to stimulate a specific immune response against human milk fat globule (HMFG), wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof, and wherein the heavy chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof.

F5
39. (Thrice amended) A composition comprising a pharmaceutically acceptable excipient and a polypeptide having immunological activity of anti-idiotype antibody 11D10, wherein the polypeptide comprises an immunoglobulin variable region containing three light chain complementarity determining regions (CDRs) of antibody 11D10, or an immunoglobulin variable region containing three heavy chain CDRs of antibody 11D10, wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC NO. HB 12020 or progeny thereof, and wherein the heavy chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC NO. HB 12020 or progeny thereof, and wherein the immunological activity of the polypeptide is an ability to stimulate a specific immune response against human milk fat globule (HMFG).

Please add the following new claims:

69. (New) The purified antibody of claim 4, said antibody comprising the sequence of SEQ ID NO:2.

70. (New) The purified antibody of claim 4, said antibody comprising the sequence of SEQ ID NO:4.

71. (New) The fusion polypeptide of claim 33, wherein the light chain variable region and the heavy chain variable region of antibody 11D10 are joined by a linker polypeptide of about 5 to 20 amino acids.

PL
72. (New) The humanized antibody of claim 35, wherein the framework regions are human sequences.

73. (New) A humanized antibody comprising three CDRs from the light chain variable region of 11D10, three CDRs from the heavy chain variable region of 11D10, and framework regions that are human sequences, wherein the humanized antibody is able to stimulate a specific immune response against human milk fat globule (HMFG), wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof, and wherein the heavy chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof.
